Embed Size (px)
Citation preview
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL More than a century of natures healthcare
INVESTOR PRESENTATIONFebruary 2020
CANNSUN MEDHELGroup of Companies
S I N C E 1 9 1 8
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
THE INVESTMENT
2
Europe’s first pharmaceuticals, cosmetics & food for special medical purposes (FSMP) manufacturer with a vertically integrated
cannabinoid division that includes EUGMP-certified manufacturing, production
and extraction
C A N N S U N M E D H E L
Established in 1918, one of the longest running pharmaceutical EUGMP-certifiedmanufacturing and distribution companies in Western Europe.
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
WHY INVEST IN CANNSUN MEDHELSTABLE, H IGH MARGIN PHARMACEUTICAL MANUFACTURING AND DISTR IBUTION
3
EUGMP certified, pharmaceutical manufacturing and distribution facility serving Europe for over 100 years
05
0401
02
03 Established distribution networks with a sales force of 30+ provide penetration in 21 countries globally
Experienced management team with a track record of building pharmaceutical businesses
Near term JV opportunities with large addressable populations and emerging botanicals and cannabinoid demand
Pharmaceutical facility is scalable to address product demands in all components of production
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
4
Current markets (direct & through partnerships)
Near-term JV opportunities
GREECE Serbia Albania ThailandMalta Croatia Indonesia UgandaCyprus Jordan Cambodia VietnamBulgaria Saudi Arabia EthiopiaQatar Egypt JamaicaLebanon South Africa Philippines
Australia Iraq United KingdomAustria Czech Republic EstoniaPoland Kazakhstan LatviaNew Zealand Germany GhanaMalaysia China IraqSlovakia Lithuania CanadaRussia Ukraine KazakhstanKyrgyzstan Georgia
ACCESS TO ESTABLISHED MARKETS
Key distribution hubs/in-country offices and staff
GREECE Poland South AfricaThailand China Malaysia
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
___
EXISTING GLOBAL DISTRIBUTION
Greece
*Pending schedule 1 license. Potential near-term markets
Africa
Asia
Europe
Current Pharmaceutical/CosmeticsFuture Botanical and Cannabinoid*
MedhelOperations
CREATING SCALABLE JOINT VENTURES SALES CHANNELS
5
92%
8%
Pharmaceutical/CosmeticsFuture Botanical and Cannabinoid*
2020 Forecast
Revenue Distribution
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
• 70,500 ft2 EUGMP certified pharmaceutical manufacturing
• Access to 100 wholesalers, 11,000 pharmacies, 35,000 doctors in over 21 countries in Europe, Asia & Africa
• Experienced management team in Greece to drive manufacturing and distribution
• Obtaining Schedule I License in Q3 2020 -importation of THC and related products
• Undertaking a full modernization and expansion of existing facilities to add additional products and capacity
PHARMACEUTICALS
MEDHEL
Projected 2020revenue of €31.0 MM
ESTABLISHED OPERATING COMMERCIAL COMPANY
Current utilization < 5%
6
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
C U R R E N T P R O D U C T O F F E R I N G S
T O P R E V E N U E P R O D U C T S
T R E A T M E N T S E G M E N T S
R x & O T C P h a r m a c e u t i c a l s
F o o d f o r S p e c i a l M e d i c a l P u r p o s e s
C o s m e t i c s
M e d i c a l D e v i c e s
F e r u m - B l o o d P r e s s u r eR e g u l a t i o n
O m e p r a z o l e –S t o m a c h / u l c e r
A v e m a r – F o o d S u p p l e m e n t
P a n t h e n o l – S k i n C r e a m
P a i n m a n a g e m e n t
C e n t r a l N e r v o u s S y s t e m
D i a b e t e s
I n s o m n i a
S t r e s s
O n c o l o g y
PRODUCT OFFERINGS & DEVELOPMENTS
7
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
85
NEW PRODUCT OFFERINGS & ADDIT IONAL NATURAL ALTERNATIVES
Supplements –Wellness Botanical
Medical Devices –Female Suppository
CBD Cosmetics and Oral Consumption
PRODUCT OFFERINGS & DEVELOPMENTS
Prescriptions – Arthritis Medication
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
9
RESEARCH + DEVELOPMENTWe are focusing on R&D-driven growth, realizing collaborations with accredited academic and research centers:
• With support from the research/academic centers we anticipate developinginnovative products that would establish cutting edge therapeutic protocols for both cannabinoid and herbal medicines
• Clinical trials that support product development create niche molecules that enable speed to market in EU, Africa & Asia
• Academy of Athens • Pasteur Institute
• Stellenbosch University
• University of Athens Greece• CRO Athens R&D
• Cape Peninsula University
9
1) Cardiovascular detection technology2) Cystic Fibrosis pain treatment
3) Fatigue medication
4) Dialysis treatment technology
Current R&D Projects
5) Neuro pain management6) Stress and anxiety treatment
7) Gynecology products
8) Cardiovascular/hypertension treatment
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
1015
PROJECTED REVENUE PROFILE
Asset purchase October 2019, Cannsun Medhel Group sales and distribution initiated December 2019
0
15
30
45
60
75
90
105
120
135
150
2020 2021 2022
Reve
nue
(€M
)
THC Sales
CBD Products
Contract Mngt Services
Selective Channel
JV Sales
Exports
OTC/Cosmetics
Food for Special MedicalNeedsPharmaceuticals (Rx)
Projected Revenue: €31.0Projected Revenue + JV: €52.0
€139.1
€101.3
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
ELNEAR TERM GROWTH + EXPANSION
Projected 2020
Growth
Product Offering Expansion
Increasing product offering from 40 to 150 SKU’s globally
Cannsun MedhelSouth Africa
Marketing and distribution of pharmaceuticals, botanical and CBD product formulations
Cannsun MedhelAsia
Agreement to manufacture products for mass market sale
Cannsun MedhelPoland
Expand distribution networks of cosmetics and medical devices
11
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
12
CAPITAL STRUCTURE
17
N U M B E R O F S H A R E S
Private Placement Closed January 2020: €4.0 million – €1.50 2,600,000
Shares Outstanding 27,515,739
Current Private Placement: €8.5 million - $1.75/share 4,900,000
Stock Options - €1.50 2,800,000
Management Milestone shares - €1.50 1,200,000
Shares Outstanding, Fully Diluted 33,615,739
Pre-Raise Market Capitalization
€50 M
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
13
ASSET VALUATION
17
A s s e t s T o t a l C a p i t a l ( $ )N e t P r e s e n t V a l u e 1 5 %
( $ )I R R ( % )
Greece – Pharmaceutical Facility 33,700,000 86,800,000 100
South Africa –Cultivation/Extraction 8,000,000 29,900,000 80
Lesotho – Cultivation 3,000,000 14,300,000 96
Greece - Cultivation 7,000,000 17,200,000 66
TOTAL 51,700,000 148,200,000
Valuation models are based on a 6-year cash flow projection (2020-2025)
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
1417
2017
Q3 2017Molodhi est’d in
Lesotho
TRACK-RECORD OF CREATING VALUE
Q1 2018Cannsun South Africa est. 23 Hectare farm
acquired
Q2 2018Agraleaf est. by
Agraflora Organics in Northern
Greece
Q4 2018Roughrider signs
agreement to acquire Molodhi -
License awarded in Q1 2019
Q2 2019Cannsun Lesotho
newly formed company
is awarded license on 2.0 hectare site
Q3 2019Cannsun
signs agreement to merge with Roughrider
Q1 202060% of
Cannsun Medhel
Commercial acquisition
Q4 2019Cannsun Medhelsigns agreement to acquire 100% Medhel Hellas
Cannsun Medhel Group plc Ireland est. company begins process to redomicile to European Union
Q1 202020%
ownership in Borealis MedhelMalaysia
Q1/Q2 2020Formation of separate
JV’s with China, Thailand & Poland. Commencing cosmetic sales in Africa.
Amalgamation of Cannsun Medhel Group
completion
1918: Medhel Greece was established – a pharmaceutical manufacture and distribution company
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
15
LEADERSHIP
19
B O A R D O F D I R E C T O R S
Chris BrocklesbyCFO of Houwelings Group
Rorisang NtaiSouth African based businessman
Stephen Polakoff Lawyer with over 20 years M&A and Capital Markets experience
Kiki KaragouniProfessor at Pasteur Institute in plant-based medicine
David ParryCo-founder of Cannsun Medhel Group
Nikos KorbisCo-Founder and Chief Medical Officer
M A N A G E M E N TNikos KorbisChief Medical Officer
David ParryChief Executive Officer
Pholoso MalatjiCo-Founder and Head of Africa Operations
Greg BealerDirector of Finance
Stephen PolakoffGeneral Counsel
Aaron KaterenchukChief Operating Officer
Artemios CharalampakisChief Commercial Officer
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
1623
B U S I N E S S U N I T L E A D E R SCannsun South AfricaPholoso Malatji
Cannsun LesothoNicodema NtaiLeondios Caldis
Cannsun Greece AgraLeafManoli KaldisStavros Baxebanakis
Cannsun Medhel Pharma Group Nikos Korbis
Cannsun Medhel AsiaBhunyanee Dethamart
Cannsun Medhel Commercial Manos Angelakis
Cannsun Medhel AfricaDonaghue Woodman
LEADERSHIPA D V I S O R Y B O A R DPeter CummingsEx-Pharmaceutical retail executive and former Head of British Columbia Hothouse growers
George VourtisPost-production cultivation expert
Eleni ChinouProfessor of Pharmacognosy and Chemistry of Natural Products, University of Athens
Chris VourtisCannabis industry expert
Vassilis DimouCorporate Finance
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
17
NEXT STEPS
1 5
• Increase product offerings of pharmaceuticals and global distribution networks
• Expansion of Greece manufacturing facility• installation of additional equipment for incremental production and packaging capacity across all SKUs
• purchasing additional dossiers for prescription product expansion
• adding extraction equipment for CBD concentrate production
• Sales team expansion
• Leverage new JV agreements in Europe and Asia
• Commence cultivation operations
• Continue to advance R&D and clinical trials
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
18
USE OF PROCEEDS
Future capital raise and IPO planned for Q4 2020, size and structure is contingent on current expansion and execution plus additional pipeline of opportunities
Capital raised on recent placements €7.0 MM, an additional €8.5 MM of capital required for facility expansion, product expansion and JV capital commitments
• Greece Facility Expansion: Equity financing €2.9 MM (€18.9 MM through German Financial Institution at 1.6% interest)
• Operating working capital: €2.0MM
• Cannsun China Joint Venture: €2.0 MM
• South Africa distribution: €0.6 MM
• South Africa cultivation:€1.0 MM
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
w w w . c a n n s u n m e d h e l . c o m
30th Km ATHINON LAVRIOUMARKOPOULO, GREECE
+30 695 100 3705
+1 604 889 2188
+30 693 603 5933
3rd FLOOR CALDIS HOUSE57A LONG STREETCAPE TOWN, 8001
REPUBLIC OF SOUTH AFRICA
+27 737 981 918
+1 780 970 3789
A F R I C A O F F I C EE U R O P E A N O F F I C E
19
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
APPENDICES
S I N C E 1 9 1 8 20
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
21
PHARMACEUTICAL PRODUCTS
5
EXTENSIVE PRODUCT OFFERING OF PHARMACEUTICAL SOLUTIONS
Prescription Drugs• Anti-inflammatories/Pain management:
Nimesulide, Dicloduo• Neurological/Central Nervous System:
Pregabalin, Rivastigmine, Risperidone, Donepezil, Quetiapine, Venlafaxine
• Oncology: Vitamin D3, Irinotecan, Capetitabine, Topotecan, Docatexel
• Anti-biotics: Macrolide, Levofloxacin• Cardiovascular: Simvastatin, Atorvastatin,
Losartan + HCTZ, Rosuvastatin, Irbesartan• Gastrointestinal: Omeprazole, Pantoprazole• Supplements: Ferum, Calcifolin
OTC Cosmetics• Anti-itch: Med Calamine• Arthritis & Pain: Med Cendium, Med Hot Ice• Facial Cream: Med Urea• Body Lotion: Med Pathenol• Hand Sanitizer: Med Care
FSMPs and Devices• Female Suppository: Lady Balance pH• Radiation & Cancer Treatment: Rad-X,
Rad-X Shampoo, Avenmar, Immax• Gastrointestinal: Glutamine Complex,
Adaptek, Nutrition Recover
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
226
S O U T H E R N A F R I C AHEMP AND CANNABIS LICENSES
Cape Town
Lesotho
TOTAL Steady State Production: 36.0 million grams/year (2024)
TOTAL Steady State Revenue: €72 million/year (€2.00/gram flower)
TOTAL CAPEX: €25 million (debt financing level 50% - €4.0 MM government grant pending)
• Cape TownAtlantis: 1 cultivation license pending, final inspection passed in December 2019. 23 hectare property with 3.0 hectare development planned for Phase 1. Tunnels currently constructed on site with flower processing facilities in place. First grow cycle planned for Q1 2020
• Lesotho Alpine: 1 cultivation license awarded, 1.5 hectare Phase 1 development, construction currently underwayMaloti: 1 cultivation licence awarded, 2.0 hectare Phase 1 development, construction commencing H2 2020
• BBBEE complaint, increasing participation of South African labour in economic activities
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
237
G R E E C EHEMP & CANNABIS LICENSES
Thessaloniki• Thessaloniki: One THC/CBD cultivation licence awarded
December 2019, 15 Hectare site in North Greece, 2.5 hectare greenhouse planned for phase 1, construction to commence 2020
• Flower used for extraction at Athens facility or for export through Schedule 1 license
• One industrial hemp license awarded in conjunction with cannabis license on property, provides flexibility in direction of operations
TOTAL Steady State Production: 22.5 million grams/year (2024)
TOTAL Steady State Revenue: €39 million/year, €1.75/gram THC flower
TOTAL CAPEX: €25 million (debt financing level 85%)
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
2423
Pholoso MalatjiPholoso is currently responsible for the South African business operations for Cannsun Medhel Africa and Co-Founder of Cannsun SA. He has over 12 years experience in property valuation, agricultural market development for emerging farmers, consulting for government Agro-projects & land reform, bio energy and research. Pholoso has extensive experience as an Agricultural Economist (MSc. Agric), Property Valuer (BSc. Property Studies), Enterprise Development (Syracuse University) and accredited with the SA Council of Scientific Professions. Pholoso worked as a consultant to the FAO, Sub-Saharan Africa in Agricultural Development and Feasibility program for four years.
David ParryCo-Founder of Cannsun South Africa and Chief Executive Officer of the Cannsun Medhel Group. David is also a Director of Propagation Services Canada one of the largest Cannabis facilities under glass in Canada, and Former Managing Director of Natures Hemp Ltd in Canada, a company developing food-based hemp products with the University of Manitoba and the Ontario Government. David has >20 years working with public and private companies in the agriculture, resource and technology sectors. He has an extensive network of contacts and relationships throughout MENA, Europe, the Former Soviet Union (FSU), Asia and Africa with significant experience in mergers and acquisitions.
LEADERSHIP BACKGROUND
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
2523
LEADERSHIP BACKGROUND Rorisang NtaiRorisang has business interests in the petroleum and property development industries. He started his career at FNB Asset Management & Trust Services, after which he worked for Citadel, eventually as an investment analyst. He has an extensive network from which he can work with relevant specialists and experts to support current business interests or new project developments. He holds a BComm from (UNISA) University of South Africa and JSE RPE Exams from (SAIFM) South African Institute of Financial Markets.
Stephen PolakoffStephen has over 20 years of experience as general counsel, legal advisor, director and project manager at corporations, funds, law firms including Deutsche Bank (UFG), Integra Group, Clifford Chance, Damac Properties and several funds. He has gathered international experience having worked in New York, Moscow, Dubai and Geneva. His experience has been very diverse across sectors and territories including joint ventures and M&A, capital markets, debt and equity financing, infrastructure and funds. He has served on the boards of AIM, TSX and AIM-listed entities as well as several funds.Stephen graduated from Georgetown University Law School and is a member of the New York Bar. He speaks English and Russian and currently resides in Barcelona.
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
2623
LEADERSHIP BACKGROUND Nickolas KorbisNickolas has a Chemistry degree from the University of Athens and a PhD in Chemical Engineering from Imperial College in London. He has received several special training courses including Commodity Trading from Wharton School (Univ. Of Pennsylvania), GMP guidelines for the Pharmaceutical Industry from Leiden University and Design for Masking Flavors for the Pharmaceutical and Foodindustry from Hercules R&D center, amongst others. He is a certified GMP by EMA auditor and has done numerous valuations and appraisals for the industry. He has been working in Greece and abroad in both technical and managerial positions. He has been R&D manager in National Starch and Chemicals, Commercial Director in Biotrek, Vice President and Commercial Director in the Hellenic Register of Shipping, COO and IR Director in Alapis (the biggest Greek Pharma Co. at that time, raising more than €1.2B in deal roadshows), President and CEO for Provet (biggest animal healthcare company in the Balkans) among others. He has participated inmore than 40 M&A’s and has set up pharmaceutical and other companies in more than 18 countries. He has also conducted severalrestructuring and financing projects creating a proven track record in these fields.
Aaron KaterenchukAaron is a professional engineer holding a BSc Engineering from the University of Alberta, Canada. Aaron has 11 years experience in oil & gas specializing in project management with recent focus in acquisitions and dispositions (closing and integrating $100+ million-dollars in transactions). More recently Aaron held a position with Vibe Bioscience as Vice President of Business Development, facilitated in the process of taking Vibe public in Spring 2019 listing on the Canadian Securities Exchange. Aaron’s core focus at Vibe was product development (THC and CBD concentrates), retail, cultivation and evaluating acquisition opportunities. He has spent four years directly involved in the cannabis space with investment in cultivation, US retail and e-commerce companies both private and public.
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
2723
Artemios CharalampakisArtemios was born in Athens Greece. He is a graduate of the Department of Earth Sciences at the University of Athens, and has an MBA from the University of Leicester with specialization in International Marketing. He has served as senior manager and as an executive with several multinational and Greek companies, such as S&V Technologies GmbH, TAD Pharma GmbH, AstraZeneca, Abbott Laboratories, ALAPIS group of companies etc. Artemios has 20 years of experience as commercial development and management in pharmaceutical, food supplements and cosmetics industries. Artemios holds the position of the Chief Commercial Officer.
Manos AngelakisManos was born in Athens Greece. A graduate of the Department of Physiotherapy in the University of Athens, he also holds a Bachelor in Business Administration from London Metropolitan University. Manos has worked for several pharmaceutical and cosmetics multinational companies as a senior manager. He also has extensive experience for over 20 years as General Manager for several companies in the Risk Management sector (Patriot Group of Companies) which was on of the biggest companies in maritime security worldwide. Manos is the main shareholder of two companies active in Risk Management (Vanguard-Risk-group) & Geostationary Satellites (Cosmos-satellites). Manos holds the position of the CEO in Cannsun-Medhel Commercial.
Manoli KaldisEmmanouil has over 20 years of experience as an architect and has also been involved in advertising, industrial design and tourism. Some of his biggest clients have included Coca Cola, Philp Morris, Nike and Harley Davidson. Manolis is the secretary of the Union of Small Hotels in Sithonia, Halkidiki and representative of the Halkidiki Tourism Federation. He is characterized by his multitasking skills complemented with his ability to speak both Greek and English.
LEADERSHIP BACKGROUND
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
2823
LEADERSHIP BACKGROUND Leondios CaldisLeondios completed his undergraduate studies in 2013, being awarded a Bachelor of Business Administration and a Diploma in International Marketing (IMM Graduate School of Marketing). In that same year, Leon ventured a start-up in the credit loan sector, partnering with African Bank. Leondios is responsible for driving Cannsun’s sales and leading the company’s marketing presence in the medical cannabis industry in South Africa. He is also heavily involved in the daily operations of the company.
Donaghue Woodman Donaghue’s role relates to regulatory aspects of the business, as well as new product and portfolio development, new business and strategic research development. She holds an MBA with a background in biochemistry and pharmacology (focusing on active molecules in natural medicines) with the South African Herbal Medicine and Science Institute. She has nine years of sales and marketingexperience within the pharmaceutical industry, in both the public and private sector, across a broad range of therapeutic areas including Woman’s health, CNS, Respiratory, Gastroenterology, Anaesthesiology, dermatology, Cystic Fibrosis, Pancreatic Cancer and Pain. Her passion is philanthropy, people and business, and she is a keynote motivational speaker for the Global Business Roundtable.
Greg BealerGreg obtained his Bachelor of Commerce degree majoring in Business Law and Economics from the University of Alberta, Canada. Greg recently retired after 11 years as an Investment Advisor and Portfolio Manager. He turned his core focus on the pharmaceutical and cannabis industry in 2013. Greg has been actively involved in financing of Canadian and international cannabis startups and brings both experience and knowledge of the capital markets.
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
2923
LEADERSHIP BACKGROUND Chris BrocklesbyChris is a CPA-CA currently holding the position of CFO for the Houwelings Group. He has also held roles with KPMG and Village Farms International Inc. where he gained expertise in US/Canada taxation, finance and operation. Chris has raised and restructured over $100m in senior and subordinate debt-related projects in Canada and the US. He is also responsible for intellectual property management, lender relationships and all legal matters. He is accountable for the Finance, Legal, IT, RiskManagement, Food and Health Compliance and HR departments for the Group of Companies. He holds a B.Sc. in Agroecology and a Diploma in Accounting from UBC.
Peter Cummings Peter currently provides financial advisory services to Agricultural Enterprises in the Horticultural and Insect Farming Sectors. Before engaging in private consultancy, Peter was the CFO for the Houwelings Group from 2003 to 2012, and the CFO for BC Hot House Foods from 1997 to 2003. Peter has had senior management roles with Shoppers Drug Mart between 1984 and 1997. He obtained his CA designation in 1982 and obtained a Bachelor of Commerce from UBC in 1978.
Vassilis DimouAfter his academic studies majoring in economics at the University of Siegen and Köln, Vassilis worked in various management positions in the area of syndication and investment and corporate banking with the strong focus on structured and international projects – Export Credit Agency (ECA) and Finance in the RES and Retrofit Finance area. Vassilis has long standing contracts to the finance executives and government, with a focus on the Greek regional economy to establish a Local (Public) Banking System for the local Greek SME Sector and the local population across the country, bridging public sector institutions and private
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
3023
LEADERSHIP BACKGROUND Evdokia KaragouniResearch Director & Member of the HPI Scientific Council. He is Head of the Microbiology Department, Group leader of the Parasite Immunology & Vaccine Development at the Laboratory of Cellular Immunology, Hellenic Pasteur Institute. Evdokia obtained her BSc in Biology at the Aristotle University of Thessaloniki in 1982, and her PhD in Immunobiology at the same University in 1989, and carried out a four year post-doctoral training at the Department of Parasitology, Evdokia joined the Laboratory of Cellular Immunology at the Hellenic Pasteur Institute (1994) as an assistant researcher, where since 2014, she held the position of the Research Director. She has published 70 original papers in peer-reviewed journals
Bhunyanee DethamartBhunyanee is a Thailand-based Chemist who has built a career working for Thailand and Italian based companies. The previous 17 years she has been with Eagle Chemical IND. of Thailand and Alpa SPA of Italy in roles from Research and Development Officer, Sales and Chief Operating Officer. In her role at Cannsun Medhel Group, Bhunyanee will directly support both the CEO and COO. She is a graduate of Sukhothai Thamathirat (Technology) University in 2002. Over the past several years, Bhunyanee has been in the Cannabis space making Bespoke cosmetics and natural medicine. She has been key figure in the project development in Asia.
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
31
CORPORATE STRUCTURE
Cannsun IP-R&DIreland
Cannsun Medhel Group PLC
Ireland
Cannsun MedhelCommercial
Greece
MedhelGreece
AgraleafGreece
Cannsun South Africa
Cannsun Lesotho
MohlodiLesotho
Cannsun EuropeGermany
Cannsun Medhel China
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
32
REVENUE PROFILE BREAKDOWN
S a l e s R e v e n u e s ( € M ) 2 0 2 0 2 0 2 1 2 0 2 2
P h a r m a c e u t i c a l s G r e e c e 8 , 2 2 2 4 9 , 4 7 7 5 8 , 3 9 3
F S M P s G r e e c e 2 , 0 2 6 8 , 3 2 4 1 4 , 9 8 0
O T C / C o s m e t i c s G r e e c e 2 , 5 2 7 4 , 3 1 6 7 , 3 3 7
E x p o r t s 6 3 0 1 , 4 1 0 2 , 0 3 2
J V S a l e s 1 , 1 0 0 2 , 7 0 0 4 , 3 0 0
S e l e c t i v e C h a n n e l s 5 , 7 7 2 1 2 , 0 5 6 1 6 , 1 3 1
C B D P r o d u c t s 3 , 1 2 3 1 0 , 6 5 1 1 9 , 5 5 0
T H C P r o d u c t s 0 4 , 0 0 0 8 , 0 0 0
C o n t r a c t e d R e v e n u e s 7 , 6 0 0 8 , 4 0 0 8 , 4 0 0
G R A N D T O T A L 3 1 , 0 0 0 1 0 1 , 3 3 5 1 3 9 , 1 2 4
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
33
1
Description Est. Cost (€ )
1. 5000 m² New Production Plant (Cytotoxic & Injectables) 9,000,000
2. 3,000 m² New Building Warehouse 2,000,000
3. Factory Renovation 6,000,000
4. Office & Basement Space Reconstruction 1,300,000
5. Security Fences, Surveillance System, Access Control 900,000
6. Industrial modifications of surrounding Area 500,000
7. New Building, educational training center, retail store 2,500,000
8. 40,000 m² Land Purchase 600,000
2
3
45
67
8
Loan A (3,4,5) 6,970,000
Loan B (2,6,7) 4,250,000
Loan C (1) 7,650,000
Equity 3,930,000
Total Investment (€) 22,800,000
MEDHEL FACILITY EXPANSION (3 YEARS)
Debt Financing level 85%Potential EU government grant of € 7.0 MM upon successful qualification
F e b r u a r y 2 0 2 0 •
CAN
NSU
N-M
EDH
EL
34
DISCLAIMERThis presentation is very forward-looking in its statements, and these statements may not be based on fact, including without limitation, statements regarding CannsunMedhel’s (“Cannsun”) expectations in respect of its ability to successfully execute its business plan; its ability to raise additional capital and fund its ongoing operations; plans forfuture growth and the direction of the business; financial projections including expected revenues, gross profits, and EBITDA (which is anon-GAAP financial measure); plans toincrease product volumes, the capacity of existing facilities, supplies from third party contractors; expected growth of the cannabis industry generally; management’sexpectations, beliefs and assumptions; events or developments that Cannsun expects to take place in the future; and general economic conditions. All statements, other thanstatements of historical facts, are forward-looking information and statements. The words “believe”, “expect”, “anticipate”, “contemplate”, “target”, “intends”, “continue”,“budget”, “estimate”, “may”, “will”, and similar expressions identify forward-looking information and statements.
Such forward-looking information and statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Cannsun as of thedate of such information and statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknownfactors could cause actual results to differ materially from those projected in the forward-looking information and statements. Such factors include, but are not limited to, theinability of Cannsun to generate sufficient revenues or raise sufficient funds to carry out its business plan; changes in government legislation, taxation, controls, regulations andpolitical or economic developments in various countries; risks associated with agriculture and cultivation activities generally, Including inclement weather, access to supply ofseeds, poor crop yields, and spoilage; compliance with import and export laws of various countries; significant fluctuations in cannabis prices and transportation costs; the riskof obtaining necessary licenses and permits; inability to identify, negotiate and complete a potential acquisition for any reason; the ability to retain key employees; dependenceon third parties for services and supplies; non-performance by contractual counterparties; general economic conditions; and the continued growth in global demand forcannabis products and the continued increase in jurisdictions legalizing cannabis; and the timely receipt of regulatory approval for Cannsun’s license applications. Theforegoing list is not exhaustive and Cannsun undertakes no obligation to update any of the foregoing except as required by law. Many of these uncertainties and contingenciescould affect Cannsun’s actual performance and cause its actual performance to differ materially from what has been expressed or implied in any forward-looking informationand statements made by, or on behalf of, Cannsun. Readers are cautioned that forward-looking information and statements are not guarantees of future performance. Therecan be no assurance that such information and statements will prove to be accurate and actual results and future events could differ materially from those acknowledged insuch information and statements.
CANNSUN disclaims any intention or obligation to update or revise any forward-looking information and statements whether as a result of new information, future events orotherwise, except to the extent required by applicable laws.
20
